The following announcement was posted on TeenScreen’s website (November 15, 2012): "Important Announcement for Schools & Communities: We are sorry to inform you that the TeenScreen National Center will be winding down its program at the end of this year. Accordingly, . . . Continue reading →
The primary promoters–inventors, one might say– of diagnosing children with "bipolar" disorder, who for over a decade, aggressively promoted the biopolar diagnosis and use of antipsychotics in children, were disciplined by Harvard University and its affiliated Massachusetts General Hospital.
An audit by Daniel Levinson, Inspector General of DHHS, confirms what has already been documented: that antipsychotics are widely misprescribed for unapproved uses and taxpayers are saddled with the high cost through Medicaid and Medicare. Continue reading →
This year alone, because of patent expirations, the drug industry will lose control over more than 10 megamedicines whose combined annual sales have neared $50 billion.
Why the tragic case of Dna Markingson and the culpability of the University of Minnesota won’t go away… Continue reading →
From 1991-2000 qui tam law suits accounted for only 9% of settlements with the government. But from 2001-2010, qui tam settlements comprised 67% of the billions in payouts Continue reading →
"When you’re selling $1 billion a year or more of a drug, it’s very tempting for a company to just ignore the traffic ticket and keep speeding.” Continue reading →
In December, 2009, Bloomberg News published an investigative report by David Evans reported, "Big Pharma’s Crime Spree" documenting major court settlements: "Pfizer, Eli Lilly & Co., Bristol-Myers Squibb Co. and four other drug companies have paid a total of $7 billion . . . Continue reading →
Rather than having a deterrent effect, the number of Big Pharma high profile criminal settlements is increasing and the settlements are getting bigger. Continue reading →
It is difficult to comprehend, why the Obama administration, which has made cost-cutting a legislative centerpiece of healthcare reform, would remove the most potent, financial penalty in its existing legal arsenal from its settlement with Pfizer. Continue reading →
Pfizer, the world’s largest drug manufacturer has the dubious distinction of being a corporate "repeat offender…" Continue reading →